Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib Maintenance in Resected EGFR+ NSCLC
NCT02430974Phase 2Unknown
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jan 2011
- Primary completion
- Jan 2016
- Modality
- Orthosteric Ligands
01
Overview
A Phase 2 trial of icotinib in non-small cell lung cancer (NSCLC), sponsored by Nanfang Hospital, Southern Medical University. Status: unknown.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02430974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02430974.